Skip to main content

COVID-19 Topic Center

Expert Insights

Commentary
By Yvette C Terrie, BS Pharm, RPh, consultant pharmacist Cardiovascular disease (CVD) continues to be the leading cause of death among both men and women in the United States, and globally with CVD contributing to 1 in 3 deaths in women annually.1 According to the CDC, while some progress has been…
Interview
By Julie Gould  We recently spoke with George R Aronoff, MD, MS, FACP, FASN, former chief of Nephrology and Hypertension at The University of Louisville School of Medicine, and currently the chief medical officer and co-inventor of Dosis, Inc, a cloud-based clinical decision support platform that…
Commentary
The US Department of Health and Human Services launched the Million Hearts Initiative 2012 with the goal to reduce tobacco use and sodium consumption and to eliminate artificial trans-fats from the food supply in clinical care. This initiative was led by the Centers for Disease Control and…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume 1, Issue 3  There is no "I" in team. As case counts continue to fall across the country, the recent approval of a third COVID-19 vaccine in the United States brings new hope to the fight against this calamitous pandemic. But…
Commentary
By Tom Kraus, Vice President of Government Relations, ASHP  We’ve reached an important milestone in combatting the COVID-19 global pandemic: there are now three viable vaccines against SARS-CoV-2 in the US.  All three FDA-authorized vaccines have – based on the available evidence – proven…
Commentary
By Damon Birkemeier, PharmD, FDA/ISMP safe medication management fellow In part I of this two-part blog, we introduced a survey conducted by the Institute for Safe Medication Practices (ISMP) that evaluated technologies, policies, and procedures in place as well as identified major safety concerns…
Commentary
By Yvette C Terrie, BS Pharm, RPh, Consultant Pharmacist Every day, health care professionals seem to learn a little more about COVID-19 as well as the medical conditions that may contribute to the severity of infection and the patient populations at greater risk for hospitalization due to severe…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS Volume 1, Issue 2 “A rose by any other name would smell as sweet” When it comes to managing patients with heart failure (HF), it’s all in the name. For patients classified as heart failure with reduced ejection fraction (HFrEF), there…
Video
Gary Kerr, PharmD, MBA, chief pharmacy officer, Baystate Health, and president of HOSP, discusses a recent open letter that the Health System Owned Speciality Pharmacy Alliance wrote to better address the challenges that many speciality pharmacies face, and explains what he hopes clinical…
Commentary
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS Volume 1, Issue 1 “Brevity is the soul of wit.” Welcome to the first installment of “Talking Therapeutics!” Each week we’re going to tackle a timely therapeutic topic by breaking it down into bite-sized talking points. The goal is to…
Back to Top